Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting by Miles, David W
CI = confidence interval; FISH = fluorescent in situ hybridisation; IHC = immunohistochemistry.
Available online http://breast-cancer-research.com/content/3/6/380
Introduction
Targeted therapies are not a new concept in the field of
breast cancer, strategies aimed at targeting the oestrogen
receptor having been with us for many years. The identifi-
cation and exploitation of other targets has taken longer
than had been hoped. It is more than 30 years since
growth receptors were identified, but only in the past
couple of years has a treatment targeting these receptors
been available.
Women whose tumours express HER-2 at high levels have
a relatively poor prognosis with a median survival of
3 years, compared with 6–7 years for HER-2-negative
cases [1]. Many studies published subsequently have
demonstrated that HER-2 overexpression is associated
with other features of a poor prognosis, namely high
tumour grade/S-phase fraction and oestrogen and proges-
terone receptor negativity [2]. In many series, however,
HER-2 status remains an independent poor prognostic
feature. Whether HER-2 status is a predictor of response
to other treatment modalities in breast cancer, namely hor-
monal and cytotoxic therapy, remains contentious. Conflict-
ing data are presented in the literature regarding the ability
of HER-2 positivity to predict relative resistance to hor-
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Abstract
Herceptin is the first therapy for breast cancer which targets an oncogene product. This humanized
antibody to HER-2 has been shown to have activity as a single agent in a phase II trial of heavily pre-
treated patients with advanced breast cancer and, in phase III studies, its use with chemotherapy is
associated with higher response rates, longer time to progression and improved survival when
compared with chemotherapy alone. Retrospective analysis of data from these pivotal trials suggests
that attributable benefit of herceptin is greater in those patients who express HER-2 at the highest
levels, that is 3+ expression by immunohistochemistry. Further analysis also implies that cases which
are positive for HER-2 by fluorescent in situ hybridization may also benefit from treatment regardless of
whether they express HER-2 at the 2+ or 3+ level. Use of herceptin as first-line therapy for metastatic
disease in early studies suggest that response rates and clinical benefit rate similar to chemotherapy
may be achievable and that survival using this sequential approach may not be compromized. Other
combinations of herceptin and chemotherapy have been investigated with phase II data suggesting
considerable activity with weekly taxol and when combined with navelbine. The non-linear
pharmacokinetics of herceptin suggest that, as doses increased, half-life increases and may be
feasible on a 3-weekly schedule. The role of herceptin in the adjuvant setting in the management of
breast cancer will be tested in randomized studies of patients who express HER-2 at the highest
levels; two of these studies have already begun.
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monal therapy and chemotherapy. The major difficulties in
interpreting these studies is that they are retrospective
analyses and, in many instances, there is no satisfactory
‘control’ arm against which to test attributable benefit of a
treatment intervention in different HER-2 subgroups. While
debate on this area is bound to continue, it seems unlikely
that prospective studies of adjuvant hormonal and/or
chemotherapy will be stratified according to HER-2 status.
Such is the conflicting nature of the literature regarding
HER-2 as a predictive factor that a rational view would be
that no active therapeutic option should be disregarded
based solely on the HER-2 status of a patient’s tumour [3].
Herceptin: pivotal trials
The two studies that led to the licensing of herceptin as
treatment for metastatic breast cancer have now been
published [4,5]. A re-analysis of data from both these
studies supports the preclinical observation of a relation-
ship between HER-2 expression and growth inhibition of
tumour cell lines by antibodies to the receptor (Genen-
tech, San Francisco, data held on file).
In the pivotal phase II study, heavily pretreated patients
whose tumour overexpressed HER-2 at the 2 and 3+
levels by immunohistochemistry (IHC) were treated with
herceptin as a single agent. Following re-analysis by a
‘response evaluation committee’, the overall response rate
in this group was 15% with a median survival of
9.1 months [4]. While this response rate itself appears
modest, it is noteworthy that the majority of these patients
had already received anthracyclines and taxoids, and
about one-quarter of patients had received a high dose
regimen of chemotherapy. In addition, those patients who
did respond to herceptin had a longer duration of
response following treatment, compared with their previ-
ous regimen of chemotherapy (9.1 months versus
5.2 months). Retrospective analysis of response rate and
median survival restricted to the patients whose tumours
overexpress HER-2 at the highest levels (immunohisto-
chemical score, 3+) had a response rate of 18% and a
median survival of 16.4 months.
In the pivotal phase III study by Slamon et al. [5], patients
were randomised to receive chemotherapy with or without
herceptin. Patients were stratified according to whether or
not adjuvant chemotherapy contained an anthracycline,
such that the majority of patients who did not have adju-
vant chemotherapy or whose adjuvant therapy did not
contain an anthracycline were randomised to doxorubicin
and cyclophosphamide with or without herceptin. In the
subgroup of patients who had received an anthracycline in
the adjuvant setting, patients were randomised to pacli-
taxel with or without herceptin.
The principle endpoint of the Slamon et al. study was
median time to progression, which for the group as a
whole was significantly longer in those patients receiving
chemotherapy with herceptin compared with chemother-
apy alone (7.4 months versus 4.6 months; P < 0.05). Time
to progression was significantly longer in each of the
chemotherapy subgroups (cyclophosphamide versus her-
ceptin + cyclophosphamide, 6.1 months versus 7.8 months;
paclitaxel versus herceptin + paclitaxel, 2.7 months versus
6.9 months). When both chemotherapy subsets were con-
sidered, a survival benefit attributable to herceptin with
chemotherapy versus chemotherapy alone was noted
(median survival, 25 months versus 20 months). This
observed survival difference was despite the fact that
nearly three-quarters of patients treated initially with
chemotherapy alone crossed over to herceptin as a single
agent on progression of disease.
It is therefore possible that any observed survival differ-
ence attributable to herceptin has been somewhat under-
estimated. Interestingly, when the benefits of herceptin
were analysed retrospectively in those patients expressing
HER-2 at the highest level (immunohistochemical score,
3+), it became apparent that the difference in most para-
meters (time to progression, response rate and survival)
was greater in those patients whose tumours expressed
HER-2 at the 3+ level compared with the group as a
whole. For example, survival in the HER-2 3+ subgroup
was 29 months for those patients receiving chemotherapy
with herceptin, compared with 20 months for those receiv-
ing chemotherapy alone [6].
The current limitation of herceptin use in combination
chemotherapy remains the cardiac dysfunction observed
as part of the pivotal phase III study and when herceptin
was combined with anthracycline. Some level of cardiac
dysfunction was observed in 27% of patients treated with
doxorubicin/cyclophosphamide with herceptin, compared
with only 7% treated with chemotherapy alone. Cardiac
dysfunction reached grade III and IV levels of the New
York Heart Association rating in 16% of patients at some
point during therapy, reducing to 6% of patients once
treatment had been completed. The aetiology of the
cardiac dysfunction remains unclear, and combinations of
herceptin with other anthracyclines, including epirubicin
and liposomal doxorubicin, remain the subject of clinical
trials. The license for herceptin in combination with
chemotherapy is therefore restricted to its use with pacli-
taxel, where the addition of herceptin increased median
survival from 18 to 25 months.
In summary, herceptin is currently licensed for use as a
single agent following anthracycline and taxoid chemother-
apy or in those patients for whom such therapies are
unsuitable, and also in combination with paclitaxel. In both
incidences, the current license restricts its use to those
patients who tumours overexpress HER-2 at the highest
level (3+) as assessed by IHC.Breast Cancer Research    Vol 3 No 6 Miles
As well as conventional endpoints, health-related quality of
life using the European Organisation for Research and
Treatment of Cancer Quality of Life questionnaire QLQ-
C30 was administered at baseline, week 8 and every
3 months thereafter. The five primary prospectively defined
quality of life domains examined included global quality of
life, physical, social and role functioning as well as fatigue.
The use of herceptin with chemotherapy was associated
with improvements in all these domains when compared
with chemotherapy alone [7].
Testing of samples for HER-2 status
Debate continues regarding the best way of testing tissue
samples for the presence of high levels of HER-2 recep-
tor. The vast majority of studies examining the use of HER-
2 overexpression as a prognostic and predictive factor
have been carried out using IHC. This is obviously a well-
established and easy to use technique that is widely avail-
able. Part of the problem encountered in interpreting the
prognostic and predictive data from HER-2 is also an
issue for testing the suitability of patients for herceptin;
IHC analysis may be subject to the vagaries of differences
in tissue fixation. In addition, the use of different antibod-
ies, other methodologies and scoring systems may render
this technique less than completely objective.
Fluorescent in situ hybridisation (FISH) detects HER-2 at
the DNA level and is specific and very sensitive. As a tech-
nique, however, it has limited availability, it is more expen-
sive than IHC and it requires specialised equipment.
Comparisons between IHC analysis and analysis by FISH
of many of the samples from the phase II and phase III
pivotal studies show a good concordance between the two
techniques. Nevertheless, from the data presented by
Mass et al. [6], it is clear that 11% of cases that were 3+
by IHC are actually FISH-negative and, conversely, a signif-
icant proportion (24%) of cases that are 2+ by IHC are
FISH-positive. Given the inherent variability of testing by
IHC, it is a concern that cases that are FISH-positive but
only 2+ by IHC might indeed benefit from herceptin,
although this has not been evaluated prospectively. Never-
theless, it is worthy of note that, for the monotherapy study,
the objective response rate in the FISH-positive group is
21% and 18% in the patients whose tumours were 3+ by
IHC. Time to progression in these two groups (IHC 3+ and
FISH-positive) were identical at 3.2 months. Similarly, in the
pivotal phase III study, response rates, time to progression
and survival were similar in those patients who were FISH-
positive compared with the group whose tumours were
IHC 3+. On these grounds, it has been suggested that
although patients whose tumours express HER-2 at the 3+
level are those most likely to benefit from herceptin,
patients whose tumours express HER-2 at the 2+ level but
who are FISH-positive should also be considered for treat-
ment with herceptin. It is expected that a license variation
will be applied for to account for this group of patients.
Future development of herceptin
First line monotherapy
Herceptin has been tested in the first line treatment of
metastatic breast cancer in patients who were unsuitable
for or who declined chemotherapy. Vogel et al. performed
a randomised phase II study comparing two different
dose schedules of herceptin [8]. A total of 114 HER-2-
positive patients were randomised to receive herceptin at
standard doses (4 mg/kg loading dose followed by
2 mg/kg weekly) or high dose (8 mg/kg loading dose fol-
lowed by 4 mg/kg weekly). Response rates in the two
groups were similar. When combined, the overall
response rate (complete plus partial responses) for the
group as a whole was 26% (95% confidence interval
[CI], 18–34%). In those patients who overexpressed
HER-2 at the 3+ level by IHC, the response rate was
noted to be 35% (95% CI, 24–44%). If disease stabilisa-
tion for longer than 6 months was added to the complete
and partial responders to define a clinical benefit rate,
then the clinical benefit rate in the patients whose
tumours expressed HER-2 at the IHC 3+ level was 48%.
It is noteworthy that no complete or partial responses
were noted in patients whose tumours expressed HER-2
at the IHC 2+ level. If only patients whose tumours
expressed HER-2 by FISH were considered, then the
overall response rate (complete and partial response)
was 41% (95% CI, 26–56%).
The 95% CIs on these response rate estimates, taking all
comers, IHC 3+ or FISH-positive patients, all overlap.
There is, however, a trend towards higher response rate in
those patients who are perhaps better defined by FISH.
Cross-trial comparisons between Vogel et al.’s study [8]
and the pivotal phase III study [5] suggest that the use of
herceptin as monotherapy in FISH-positive patients rather
than in combination may not ultimately compromise
outcome. The median survival in 41 patients who were
FISH-positive receiving herceptin as first line monotherapy
was 23 months, compared with a median survival of
26.8 months in a 125 patients from the pivotal study who
had herceptin in combination with chemotherapy. While
logistically difficult, a sequential versus combination study
would be informative in this respect.
Herceptin in combination with other agents
The combination of herceptin and navelbine has been
tested in the phase II setting [9]. The overall response
rate to the combination in patients with metastatic
disease was 75%, and when considering patients whose
tumours overexpressed HER-2 at the IHC 3+ level the
overall response rate was 80%. The combination was
well tolerated and clearly warrants further investigation.
Given the weekly schedule of herceptin and the observa-
tions that weekly paclitaxel has relatively high activity, the
combination of herceptin and weekly paclitaxel was a
logical one to pursue.Available online http://breast-cancer-research.com/content/3/6/380
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
Seidman et al. examined the use of herceptin and pacli-
taxel in patients with metastatic disease irrespective of
HER-2 status [10]. The original intention of the study
was to compare roughly equal numbers of HER-2-posi-
tive and HER-2-negative patients and to make compar-
isons of response rate according to different assay
techniques. Overall, the combination was associated
with response rates of 80% in patients who were HER-
2-positive and only 43% in patients who were HER-2-
negative. Response was probably better defined by the
use of the monoclonal antibody, TAB 250, rather than
the now more widely used HercepTest kit. Given the rel-
ative lack of efficacy of herceptin in HER-2-negative
patients, it seems unlikely that this will be the subject of
much further study. Whether the weekly schedule of
paclitaxel in combination with herceptin is superior to the
3-weekly schedule in those patients whose tumours
overexpress HER-2 will clearly need to be tested in the
context of a randomised study.
Given the observed cardiotoxicity in the pivotal phase III
trial, current combinations of herceptin and anthracyclines
are in the minority. Some groups are, however, investigat-
ing the possible use of the slightly less cardiotoxic epiru-
bicin as well as liposomal doxorubicin. A current
randomised phase II study is examining the contribution of
herceptin to docetaxel as first line therapy for metastatic
disease. Preclinical data suggest that one of the more
potent ‘synergistic’ combinations of herceptin would be
with platinum and a taxoid. Studies by Slamon et al. have
examined this combination [11].
Herceptin dose scheduling
Increasing the dose interval of herceptin would obvi-
ously be more convenient, would increase patient com-
pliance and would render more feasible studies of
herceptin in the adjuvant setting. Pharmacokinetic mod-
elling suggest that a 3-weekly administration may be
feasible. This is largely on the basis that herceptin
demonstrates dose-dependent non-linear pharmacoki-
netics with faster clearance and shorter half-life at
doses less than 100 mg. More recent data from Gelmon
et al. assess the toxicity and safety of 3-weekly her-
ceptin and paclitaxel [12]. Herceptin was given at a
loading dose of 8 mg/kg with subsequent doses of
6 mg/kg every 3 weeks. Overall, the half-life of herceptin
in this study was in the order of 21 days. Biological rele-
vant trough levels were attained in a similar time period
to the schedule of weekly administration. A similar
profile of toxicity in reduction in left ventricular ejection
fraction was noted as for weekly administration. Her-
ceptin given every 3 weeks is clearly a feasible sched-
ule. It is noteworthy, however, that with a half-life of
21 days, total clearance of herceptin could take up to
18 weeks, which might have implications for anthracy-
cline regimens following discontinuation of herceptin.
Herceptin in the adjuvant setting
HER-2 amplification and overexpression is clearly an early
event in the pathogenesis of breast cancer. Indeed, over-
expression in ductal carcinoma in situ is significantly
higher than in invasive disease (reviewed in [2]). With the
observation of the activity of herceptin as single agent
therapy and considering its capacity to improve survival in
metastatic disease when used in combination with
chemotherapy, the development of adjuvant studies was
clearly logical.
The NSABP B31 study compares paclitaxel with paclitaxel
and concurrent herceptin following four cycles of
cyclophosphamide. Eligible patients are those with
tumours overexpressing HER-2 at the 3+ level by IHC or
those who are FISH-positive. It is expected that 2700
patients will accrue to this study. The intergroup trial
N9831 is similar to NSABP B31, but as a three-arm study
that compared paclitaxel alone with paclitaxel and concur-
rent herceptin versus paclitaxel followed by herceptin.
Again, eligible patients are those who express HER-2 at
the highest levels by IHC or FISH. One thousand patients
per arm will be accrued over 4.5 years. In both these
studies, cardiac safety is being monitored carefully with
safety analyses after predetermined levels of accrual.
The BCIRG trial of herceptin in the adjuvant setting is also
a three-arm study, which tests the use of docetaxel follow-
ing four courses of cyclophosphamide with docetaxel and
herceptin given on a weekly schedule for 1 year. The third
arm of this study aims to compare these ‘standard’ anthra-
cycline style regimens with docetaxel and cisplatin or car-
boplatin times six with weekly herceptin for 1 year. The
herceptin adjuvant trial is a slightly more pragmatic study
in which eligible patients (tumour HER-2 3+ or FISH-posi-
tive) complete primary management with chemotherapy
and possibly radiotherapy, and are stratified by type of
chemotherapy to one of three arms: mainly observation,
herceptin given on a 3-weekly schedule for 12 months,
and herceptin given on a 3-weekly schedule for
24 months. This is the only current randomised adjuvant
trial proposed that uses the 3-weekly schedule and is also
testing two durations of herceptin. Again, cardiac function
is being monitored closely.
Conclusions
HER-2 testing should be considered in patients with
breast cancer, based not only on its potential usefulness
as a prognostic or predictive factor, but more to define
whether the humanised monoclonal antibody to this
growth factor receptor may be of use in patient manage-
ment. The use of herceptin in combination with
chemotherapy has been demonstrated to prolong survival
in women with metastatic breast cancer. Sadly, very few
agents have demonstrated such a benefit in this setting
and, certainly, the additional toxicity associated with thisBreast Cancer Research    Vol 3 No 6 Miles
benefit seems small. New combinations and schedules
using herceptin seem very promising, but will need to be
tested further. The role of this agent and the adjuvant
treatment of breast cancer will be tested in the adjuvant
studies currently ongoing.
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